Global Cardiac Biomarkers Market Growth (Status and Outlook) 2023-2029

Global Cardiac Biomarkers Market Growth (Status and Outlook) 2023-2029

Cardiovascular diseases are leading cause of morbidity and mortality globally. Biomarkers are generally used as an indicator forparticular diseases such as rheumatic and congenital heart diseases and cardiac arrhythmia. Cardiac biomarkers are measurable and quantifiable biological parameters. These are specifically used to check the presence or severity of cardiovascular diseases. Cardiac biomarkers are the substances that are released into blood when heart is damaged. These biomarkers are also used for diagnosing and monitoring diseases such as coronary syndrome or cardiac ischemia. The symptoms of these diseases includes chest pain, shortness of breath and nausea that ultimately leads to heart attack or angina. Cardiac biomarker tests helps to detect presence of coronary syndrome and cardiac ischemia to evaluate its severity and diagnosis.

LPI (LP Information)' newest research report, the “Cardiac Biomarkers Industry Forecast” looks at past sales and reviews total world Cardiac Biomarkers sales in 2022, providing a comprehensive analysis by region and market sector of projected Cardiac Biomarkers sales for 2023 through 2029. With Cardiac Biomarkers sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cardiac Biomarkers industry.

This Insight Report provides a comprehensive analysis of the global Cardiac Biomarkers landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cardiac Biomarkers portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cardiac Biomarkers market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cardiac Biomarkers and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cardiac Biomarkers.

The global Cardiac Biomarkers market size is projected to grow from US$ 688.9 million in 2022 to US$ 1306.9 million in 2029; it is expected to grow at a CAGR of 9.6% from 2023 to 2029.

The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state and used for diagnostic and prognostic purposes associated with heart. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others. Cardiac biomarkers market has witnessed a greater demand over the past five to six years. 

This report presents a comprehensive overview, market shares, and growth opportunities of Cardiac Biomarkers market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Troponin
CK-MB
Natriuretic Peptides - BNP and NT-proBNP
Myoglobin
Others

Segmentation by application
Acute Coronary Syndrome
Myocardial Infarction
Congestive Heart Failure
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
Abbott
F. Hoffmann-La Roche
Advanced ImmunoChemical
AgPlus Diagnostics
BG Medicine
BioLegend
bioMérieux
Bio-Rad Laboratories
BODITECH MED

Please note: The report will take approximately 2 business days to prepare and deliver.